Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6300101
Methods and compositions including a 13kD B. burgdorferi protein
expired -
US 6300104
Secretory immunoglobulin produced by single cells and methods for making and using same
expired -
US 6299898
Methods and compositions for the treatment of wounds
expired -
US 6299897
Inhibition of selectin binding
expired -
US 6296849
Methods and compositions including a 13kDa B. burgdorferi protein
expired -
US 6296848
GRB2 associating polypeptides and nucleic acids encoding therefor
expired -
US 6297219
Site-specific instillation of cells or site-specific transformation of cells and kits therefor
expired -
US 6294650
Inhibition of mammalian telomerase by peptide nucleic acids
expired -
US 6294379
Efficient AAV vectors
expired -
US 6294169
Interleukin-1 beta converting enzyme like apoptotic protease-6
expired -
US 6291431
Methods and compositions for the treatment and prevention of Staphylococcal infections
expired -
US 6291220
Polynucleotides encoding phosphatidylinositol 3-kinases
expired -
US 6291637
Interference with viral IRES-mediated translation by a small yeast RNA reveals critical RNA-protein interactions
expired -
US 6291501
Compounds and methods of use for treatment of neurogenic inflammation
expired -
US 6291642
Mammalian cell cycle protein
expired -
US 6291652
Antibodies specific for proteins having polyglutamine expansions
expired -
US 6291654
Method for isolating a C3 binding protein of streptococcus pneumoniae
expired -
US 6291743
Transgenic plants expressing mutant geminivirus AC1 or C1 genes
expired -
US 6287792
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
expired -
US 6287537
Radioimmunotherapy of lymphoma using anti-CD20 antibodies
expired -
US 6287569
Vaccines with enhanced intracellular processing
expired -
US 6287556
Intracellular delivery vehicles
expired -
US 6287575
Vaccine against papillomatous digital dermatitis (PDD)
expired -
US 6287607
Potassium calcium citrate compositions and methods therefor
expired -
US 6284242
Method for enhancing myoblast migration and invasion in the context of gene therapy
expired -
US 6284258
Long-acting, chemical-resistant skin emollients, moisturizers, and strengtheners
expired -
US 6284536
Modified immunoglobin molecules and methods for use thereof
expired -
US 6280964
Binding sites for phosphotyrosine binding domains
expired -
US 6281256
Open pore biodegradable matrices
expired -
US 6281196
Isolation and structural elucidation of the human cancer cell growth inhibitory compound denominated agelagalastatin
expired -
US 6280958
Rh blood group antigen compositions and methods of use
expired -
US 6277593
Dorsal tissue affecting factor and compositions
expired -
US 6277557
Infusible grade short-term cell storage medium
expired -
US 6277368
Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
expired -
US 6277585
Netrin receptors
expired -
US 6277375
Immunoglobulin-like domains with increased half-lives
expired -
US 6277586
Cloned glutamic acid decarboxylase
expired -
US 6278040
Receptor-deficient mice and cell lines derived therefrom, and uses thereof
expired -
US 6274119
Methods for labeling .beta.-amyloid plaques and neurofibrillary tangles
expired -
US 6274116
Compositions for boron delivery to mammalian tissue
expired -
US 6274702
Bone stimulating factor
expired -
US 6274729
Use of long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis
expired -
US 6271239
Delta opioid receptor-selective benzylidene-substituted morphinans
expired -
US 6271207
Enhanced expression of transgenes
expired -
US 6271201
Methods for the selective regulation of placental prostanoids and inhibition of labor using IGF-I
expired -
US 6271196
Methods of alleviating neuropathic pain using prosaposin-derived peptides
expired -
US 6270995
Recombinant polynucleotides encoding a slit polypeptide
expired -
US 6270954
Correction of genetic defects using chemical chaperones
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory